Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 2
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean tonini g[au] (955 results)?
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: topini g. Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10. Cancer Immunol Immunother. 2023. PMID: 37428196 Free PMC article.
External validation of the accuracy of 'CLLflow score'.
D'Arena G, Vitale C, Coscia M, D'Auria F, Bellesi S, Topini G, Panichi V, Valvano L, Statuto T, Corrente F, Laurenti L. D'Arena G, et al. Among authors: topini g. J Investig Med. 2018 Oct;66(7):e6. doi: 10.1136/jim-2018-000832. Epub 2018 Sep 14. J Investig Med. 2018. PMID: 30217834 No abstract available.
Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy.
Nelli F, Panichi V, Fabbri A, Natoni F, Giannarelli D, Topini G, Virtuoso A, Giron Berrios JR, Marrucci E, Pessina G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: topini g. Cancer Invest. 2022 Sep;40(8):710-721. doi: 10.1080/07357907.2022.2092635. Epub 2022 Jun 26. Cancer Invest. 2022. PMID: 35736808
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A, Panichi V, Topini G, Pessina G, Natoni F, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: topini g. Ann Oncol. 2022 Jul;33(7):740-742. doi: 10.1016/j.annonc.2022.04.002. Epub 2022 Apr 9. Ann Oncol. 2022. PMID: 35413398 Free PMC article. No abstract available.
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
Ruggeri EM, Nelli F, Giannarelli D, Fabbri A, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Fiore C, Panichi V, Topini G, Silvestri MA. Ruggeri EM, et al. Among authors: topini g. Sci Rep. 2022 Dec 19;12(1):21908. doi: 10.1038/s41598-022-25558-8. Sci Rep. 2022. PMID: 36535985 Free PMC article.
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Trapè G, De Angelis G, Morucci M, Tarnani M, De Gregoris C, Di Veroli A, Panichi V, Topini G, Bassi L, Isidori R, Poscente M, Innocenti V, Cippitelli EE, Talucci R, Bertelli S, Crocicchia A, Lippi A, Pezzuti G, Fuschino M, Randi R, Mastini C, Ciambella S, Pessina G, Montanaro M, Latagliata R. Trapè G, et al. Among authors: topini g. Eur J Haematol. 2023 Aug;111(2):311-317. doi: 10.1111/ejh.14012. Epub 2023 May 26. Eur J Haematol. 2023. PMID: 37231885
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.
Nelli F, Signorelli C, Fabbri A, Giannarelli D, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: topini g. Cancers (Basel). 2023 Jul 14;15(14):3625. doi: 10.3390/cancers15143625. Cancers (Basel). 2023. PMID: 37509286 Free PMC article.
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study.
Nelli F, Fabbri A, Panichi V, Giannarelli D, Topini G, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: topini g. Int Immunopharmacol. 2022 Jul;108:108774. doi: 10.1016/j.intimp.2022.108774. Epub 2022 Apr 14. Int Immunopharmacol. 2022. PMID: 35461110 Free PMC article.
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.
D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L. D'Arena G, et al. Among authors: topini g. Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. Online ahead of print. Hematol Oncol. 2018. PMID: 29602219